Exagen to Announce Fourth Quarter and Full Year Financial Results on March 16, 2021
Exagen Inc. (Nasdaq: XGN) is set to release its financial results for the fourth quarter and full year ending December 31, 2020, on March 16, 2021, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Exagen Inc. (Nasdaq: XGN) is set to release its financial results for the fourth quarter and full year ending December 31, 2020, on March 16, 2021, after market close. The conference call will be led by CEO Ron Rocca and CFO Kamal Adawi at 4:30 PM ET. Interested participants can join via phone or webcast through the Exagen investor relations website. A replay will be available until March 23, 2021. Exagen focuses on innovative testing products for autoimmune diseases, aiming to enhance provider capabilities in diagnosing and managing conditions like rheumatoid arthritis and lupus.
Positive
- Focus on innovative testing products under AVISE® brand.
- Goal to improve patient care in autoimmune diseases.
Negative
- None.
Details
News Market Reaction – XGN
The recorded move for XGN in the trading session of this news was +6.75%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, will release financial results for the quarter and year ended December 31, 2020 after the market close on Tuesday, March 16, 2021. Ron Rocca, President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 4:30 PM Eastern Time (1:30 PM Pacific Time).
Interested parties may access the conference call by dialing (877) 407-3982 (U.S.) or (201) 493-6780 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at https://investors.exagen.com/
A replay of the conference call will be available until Tuesday, March 23, 2021 at 11:59 PM Eastern Time (8:59 PM Pacific Time). Interested parties may access the replay of the conference call by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) using passcode 13716870. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately 30 minutes after the call concludes.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus. For further information please visit www.exagen.com.
CONTACTS:
Investors
Westwicke Partners
Mike Cavanaugh
Mike.Cavanaugh@westwicke.com
646.677.1838
Company Contact
Exagen Inc.
Kamal Adawi, Chief Financial Officer
KAdawi@exagen.com
760.477.5514
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.